Overall, increased levels of CTC–neutrophil clusters are associated with a poorer prognosis in breast cancer patients [110], suggesting that the PD-L1 positive CTCs or CTCs/immune cell clusters might also have a potential to be a biomarker for anti-PD-(L)1 immunotherapy [111,112]. This evidence concerns the gene CD274 and breast cancer.